Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker.

Martins TA, Kaymak D, Tatari N, Gerster F, Hogan S, Ritz MF, Sabatino V, Wieboldt R, Bartoszek EM, McDaid M, Gerber A, Buck A, Beshirova A, Heider A, Shekarian T, Mohamed H, Etter MM, Schmassmann P, Abel I, Boulay JL, Saito Y, Mariani L, Guzman R, Snijder B, Weiss T, Läubli H, Hutter G

Open source

DOI: 10.1038/s41467-024-54129-w
Published: 2024 Nov 9
Container: Nature communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-024-54129-w,
  title = {Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker.},
  author = {Martins TA and Kaymak D and Tatari N and Gerster F and Hogan S and Ritz MF and Sabatino V and Wieboldt R and Bartoszek EM and McDaid M and Gerber A and Buck A and Beshirova A and Heider A and Shekarian T and Mohamed H and Etter MM and Schmassmann P and Abel I and Boulay JL and Saito Y and Mariani L and Guzman R and Snijder B and Weiss T and Läubli H and Hutter G},
  year = {2024},
  journal = {Nature communications},
  doi = {10.1038/s41467-024-54129-w},
  url = {https://doi.org/10.1038/s41467-024-54129-w}
}

RIS

TY  - JOUR
TI  - Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker.
AU  - Martins TA
AU  - Kaymak D
AU  - Tatari N
AU  - Gerster F
AU  - Hogan S
AU  - Ritz MF
AU  - Sabatino V
AU  - Wieboldt R
AU  - Bartoszek EM
AU  - McDaid M
AU  - Gerber A
AU  - Buck A
AU  - Beshirova A
AU  - Heider A
AU  - Shekarian T
AU  - Mohamed H
AU  - Etter MM
AU  - Schmassmann P
AU  - Abel I
AU  - Boulay JL
AU  - Saito Y
AU  - Mariani L
AU  - Guzman R
AU  - Snijder B
AU  - Weiss T
AU  - Läubli H
AU  - Hutter G
PY  - 2024
JO  - Nature communications
DO  - 10.1038/s41467-024-54129-w
UR  - https://doi.org/10.1038/s41467-024-54129-w
ER  -

APA

TA, M., D, K., N, T., F, G., S, H., MF, R., V, S., R, W., EM, B., M, M., A, G., A, B., A, B., A, H., T, S., H, M., MM, E., P, S., I, A., JL, B., Y, S., L, M., R, G., B, S., T, W., H, L., & G, H. (2024). Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker.. Nature communications. https://doi.org/10.1038/s41467-024-54129-w

Source records

pubmed · retrieved 2026-09-25T22:22:36.624Z